Background: Medical treatment is a substantial therapeutic measure to achieve glycemic control and prevent hypoglycemic brain damage without surgery in patients with congenital hyperinsulinism (CHI). However, only few drugs are available and even fewer are approved as a medical therapy to maintain normal blood glucose levels. The established therapies are demanding for caregivers and complicated by different side effects such as gastrointestinal symptoms, hypertrichosis, and obesity. Therefore, it is important to develop new strategies to improve blood glucose control. Methods: We report the use of the very-long-acting somatostatin analogue lanreotide autogel in 6 patients with CHI over a mean duration of 40.8 months. Blood glucose levels before and after the start and dosage titration of lanreotide in these patients are compared. Results: In 3 of 6 patients, switching to lanreotide raised mean blood glucose levels and reduced individually as well as overall the risk for hypoglycemic episodes (odds ratio 0.38) significantly. Conclusion: Lanreotide autogel can be used as an alternative pharmacological treatment and may be beneficial in conservatively treated patients with CHI.

Keywords:
Congenital hyperinsulinism, Lanreotide, Beta cell, Treatment, Insulin
1.
Hussain K: Insights in congenital hyperinsulinism. Endocr Dev 2007;11:106–121.
2.
Mohnike K, Blankenstein O, Christesen HT, De Lonlay J, Hussain K, Koopmans KP, Minn H, Mohnike W, Mutair A, Otonkoski T, Rahier J, Ribeiro M, Schoenle E, Fekete CN: Proposal for a standardized protocol for 18F-DOPA-PET (PET/CT) in congenital hyperinsulinism. Horm Res 2006;66:40–42.
3.
Hussain K: Diagnosis and management of hyperinsulinaemic hypoglycaemia of infancy. Horm Res 2008;69:2–13.
4.
Beltrand J, Caquard M, Arnoux JB, Laborde K, Velho G, Verkarre V, Rahier J, Brunelle F, Nihoul-Fekete C, Saudubray JM, Robert JJ, de Lonlay P: Glucose metabolism in 105 children and adolescents after pancreatectomy for congenital hyperinsulinism. Diabetes Care 2012;35:198–203.
5.
Pierro A, Nah SA: Surgical management of congenital hyperinsulinism of infancy. Semin Pediatr Surg 2011;20:50–53.
6.
Meissner T, Wendel U, Burgard P, Schaetzle S, Mayatepek E: Long-term follow-up of 114 patients with congenital hyperinsulinism. Eur J Endocrinol 2003;149:43–51.
7.
Beltrand J, Caquard M, Arnoux JB, Laborde K, Velho G, Verkarre V, Rahier J, Brunelle F, Nihoul-Fekete C, Saudubray JM, Robert JJ, de Lonlay P: Glucose metabolism in 105 children and adolescents after pancreatectomy for congenital hyperinsulinism. Diabetes Care 2012;35:198–203.
8.
Cherian MP, Abduljabbar MA: Persistent hyperinsulinemic hypoglycemia of infancy: long-term outcome following 95% pancreatectomy. J Pediatr Endocrinol Metab 2005;18:1441–1448.
9.
De Lonlay P, Fournet JC, Touati G, Groos MS, Martin D, Sevin C, Delagne V, Mayaud C, Chigot V, Sempoux C, Brusset MC, Laborde K, Bellane-Chantelot C, Vassault A, Rahier J, Junien C, Brunelle F, Nihoul-Fekete C, Saudubray JM, Robert JJ: Heterogeneity of persistent hyperinsulinaemic hypoglycaemia. A series of 175 cases. Eur J Pediatr 2002;161:37–48.
10.
Kapoor RR, Flanagan SE, James C, Shield J, Ellard S, Hussain K: Hyperinsulinaemic hypoglycaemia. Arch Dis Child 2009;94:450–457.
11.
Aynsley-Green A, Hussain K, Hall J, Saudubray JM, Nihoul-Fekete C, De Lonlay-Debeney P, Brunelle F, Otonkoski T, Thornton P, Lindley KJ: Practical management of hyperinsulinism in infancy. Arch Dis Child Fetal Neonatal Ed 2000;82:F98–F107.
12.
Bas F, Darendeliler F, Demirkol D, Bundak R, Saka N, Gunoz H: Successful therapy with calcium channel blocker (nifedipine) in persistent neonatal hyperinsulinemic hypoglycemia of infancy. J Pediatr Endocrinol Metab 1999;12:873–878.
13.
Feelders RA, Hofland LJ, van Aken MO, Neggers SJ, Lamberts SW, de Herder WW, van der Lely AJ: Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs 2009;69:2207–2226.
14.
Kelly P, Maher KT, Chew SL, Monson JP, Grossman AB, Jenkins PJ: A single-center open-label study to investigate the efficacy and safety of repeated subcutaneous injections of lanreotide autogel in patients with acromegaly previously treated with octreotide. Endocr Pract 2010;16:191–197.
15.
Ruszniewski P, Ish-Shalom S, Wymenga M, O’Toole D, Arnold R, Tomassetti P, Bax N, Caplin M, Eriksson B, Glaser B, Ducreux M, Lombard-Bohas C, de Herder WW, Delle Fave G, Reed N, Seitz JF, Van Cutsem E, Grossman A, Rougier P, Schmidt W, Wiedenmann B: Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 2004;80:244–251.
16.
Chanson P, Borson-Chazot F, Kuhn JM, Blumberg J, Maisonobe P, Delemer B: Control of IGF-I levels with titrated dosing of lanreotide autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf) 2008;69:299–305.
17.
Caron P, Bex M, Cullen DR, Feldt-Rasmussen U, Pico Alfonso AM, Pynka S, Racz K, Schopohl J, Tabarin A, Valimaki MJ: One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide autogel. Clin Endocrinol (Oxf) 2004;60:734–740.
18.
Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn JM: Effectiveness and tolerability of 3-year lanreotide autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf) 2006;64:209–214.
19.
Hu M, Tomlinson B: Pharmacokinetic evaluation of lanreotide. Expert Opin Drug Metab Toxicol 2010;6:1301–1312.
20.
Carel JC, Blumberg J, Bougeard-Julien M, Rochiccioli P, Chaussain JL, Tauber M: Long-acting lanreotide in adolescent girls with constitutional tall stature. Horm Res 2009;71:228–236.
21.
Kuehnen P, Marquard J, Meissner T, Blankenstein O: Successful long-term treatment of congenital hyperinsulinism with lanreotide: 8th LWPES/ESPE Joint Meeting, in collaboration with APEG, APPES, JSPE and SLEP, New York, N.Y. Horm Res 2009;72(suppl 73):158.
22.
Modan-Moses D, Koren I, Mazor-Aronovitch K, Pinhas-Hamiel O, Landau H: Treatment of congenital hyperinsulinism with lanreotide acetate (Somatuline Autogel). J Clin Endocrinol Metab 2011;96:2312–2317.
23.
Koh TH, Eyre JA, Aynsley-Green A: Neonatal hypoglycaemia – the controversy regarding definition. Arch Dis Child 1988;63:1386–1388.
24.
Hartman AF, Jaundon JC: Hypoglycaemia. J Pediatr 1937;11:1–36.
25.
Rozance PJ, Hay WW Jr: Describing hypoglycemia – definition or operational threshold? Early Hum Dev 2010;86:275–280.
26.
Alkalay AL, Sarnat HB, Flores-Sarnat L, Elashoff JD, Farber SJ, Simmons CF: Population meta-analysis of low plasma glucose thresholds in full-term normal newborns. Am J Perinatol 2006;23:115–119.
27.
Le Quan Sang KH, Arnoux JB, Mamoune A, Saint-Martin C, Bellanne-Chantelot C, Valayannopoulos V, Brassier A, Kayirangwa H, Barbier V, Broissand C, Fabreguettes JR, Charron B, Thalabard JC, de Lonlay P: Successful treatment of congenital hyperinsulinism with long-acting release octreotide. Eur J Endocrinol 2012;166:333–339.
28.
Straussman S, Levitsky LL: Neonatal hypoglycemia. Curr Opin Endocrinol Diabetes Obes 2010;17:20–24.
29.
Glaser B, Landaw H: Long-term treatment with the somatostatin analogue SMS 201-995: alternative to pancreatectomy in persistent hyperinsulinaemic hypoglycaemia of infancy. Digestion 1990;45(suppl 1):27–35.
30.
Thornton PS, Alter CA, Katz LE, Baker L, Stanley CA: Short- and long-term use of octreotide in the treatment of congenital hyperinsulinism. J Pediatr 1993;123:637–643.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.